Dimerix Limited
ASX:DXB.AX
Overview | Financials
Company Name | Dimerix Limited |
Symbol | DXB.AX |
Currency | AUD |
Price | 0.38 |
Market Cap | 209,258,780 |
Dividend Yield | 0% |
52-week-range | 0.061 - 0.665 |
Industry | Biotechnology |
Sector | Healthcare |
CEO | Dr. Nina Webster B.Sc., M.B.A., M.IP.Law, MBA, Ph.D. |
Website | https://dimerix.com |
An error occurred while fetching data.
About Dimerix Limited
Dimerix Limited, a biopharmaceutical company, develops and commercializes pharmaceutical products for unmet medical needs. It develops DMX-200 that is in two Phase 3 clinical trials for COVID respiratory complications; DMX-200, a Phase 3 clinical trial for focal segmental glomerulosclerosis disease; DMX-200 for diabetic kidney disease; and DMX-700 for chronic obstructive
Related Stocks
Financials
Numbers are in millions USD
Numbers are in millions USD